New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

CASI Pharmaceuticals Inc. (CASIF) vs Dyadic International Inc. (DYAI)

CASI Pharmaceuticals Inc. and Dyadic International Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and Dyadic International Inc. are of similar size ($12.5M and $12.4M). Dyadic International Inc. grew revenue faster over the last twelve months: −7.64% against −27.4%. Dyadic International Inc. has the higher net margin (−226.9% vs −232.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Dyadic International Inc. leads on 8 and CASI Pharmaceuticals Inc. on 7.

Valuation

Metric CASIF DYAI Biotechnology median
P/E n/m n/m 8.49
P/S 0.10 3.60 8.56
P/B n/m n/m 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 0.87 3.28 8.00
Earnings yield (2,455.91%) (70.83%) (35.81%)
Free cash flow yield (3,455.46%) (63.36%) (25.41%)

Profitability

Metric CASIF DYAI Biotechnology median
Gross margin 48.65% 17.85% 70.18%
Operating margin (206.87%) (237.12%) 0.00%
Net margin (232.03%) (226.87%) 0.00%
Free cash flow margin — (227.93%) 0.00%
Return on equity 271.28% (47,316.89%) (51.58%)
Return on assets (121.17%) (71.43%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CASIF DYAI Biotechnology median
Revenue growth (TTM) (27.42%) (7.64%) 7.20%
EPS growth (last fiscal year) (1.17%) (15.00%) 29.04%
Revenue growth, 5-year CAGR 6.47% 14.04% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CASIF DYAI Biotechnology median
Debt to equity (0.34) (1.96) 0.00
Current ratio 0.15 1.69 4.79
Net debt to EBITDA (0.43) 0.49 1.01

Dividend

Metric CASIF DYAI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CASIF DYAI Biotechnology median
Market cap 12.39m 12.46m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack